The FDA has expanded its approval of durvalumab to include treating patients with unresectable stage III non–small cell lung cancer (NSCLC) whose tumors haven’t progressed following chemoradiation.
Marketed as Imfinzi, durvalumab was approved in 2017 for certain patients with locally advanced or metastatic bladder cancer. The drug is a human monoclonal antibody that binds to programmed death ligand 1 and blocks its ability to help tumors evade an immune system attack.
Voelker R. Reducing Lung Cancer Progression With Immunotherapy. JAMA. 2018;319(13):1314. doi:10.1001/jama.2018.2928
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: